We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 137

Court of Appeal strikes paragraphs relating to issue estoppel and abuse of process from statement of defence

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • March 21 2011

The Court of Appeal heard an appeal from the Motions Judge where the majority of impugned paragraphs in the Statement of Defence were allowed to stand

Merck-Frosst Schering Pharma GP v. Teva Canada

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • September 29 2010

The Federal Court granted a prohibition order, holding that Teva's allegation that the patent at issue was obvious was not justified

Patent Appeal Board has jurisdiction to consider new defects introduced by the applicants amendments made in response to a final action

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • March 26 2012

The application relates to a dual balloon catheter

Lilly v. Apotex

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • September 29 2010

Eli Lilly brought suit against Apotex alleging that it infringed eight (8) process patents

Costs awarded seven years after discontinuance

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • December 21 2010

This decision relates to a motion brought by Bayer for an order for costs of an application brought pursuant to the Patented Medicines (Notice of Compliance) Regulations

Novo Nordisk v. Cobalt

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • August 18 2010

The Trial Judge dismissed an application seeking to prohibit Cobalt from coming to market with its generic repaglinide product

Causes of action found against Pfizer for a BC class-action certification based on the VIAGRA patent

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • August 14 2014

Pfizer had a Canadian patent for VIAGRA that was found to not comply with the disclosure requirement by the Supreme Court in an earlier PM(NOC

Other industry news

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • October 27 2010

The Government has published amendments to the Patented Medicines (Notice of Compliance) Regulations

The Court of Appeal sends s.8 case back to trial judge for redetermination

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • March 26 2012

The Federal Court of Appeal (FCA) has granted Apotex’ appeal and sent a case considering s. 8 of the Patented Medicines (Notice of Compliance) Regulations (the Regulations) back to the Trial Judge for redetermination

Pfizer Canada Inc. v. Novopharm, The Minister of Health, Northwestern University and the Board of Regents for the University of Oklahoma

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • July 5 2010

In a proceeding pursuant to the Patented Medicines (Notice of Compliance) Regulations, Novopharm brought a motion seeking a Protective Order that allowed the designation of Novopharm's Notice of Allegation (NOA) as confidential